- Home
- SGC vs CYBN Comparison
SGC vs CYBN Comparison
Compare SGC & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGC
- CYBN
- Stock Information
- Founded
- SGC 1920
- CYBN 2019
- Country
- SGC United States
- CYBN Canada
- Employees
- SGC N/A
- CYBN N/A
- Industry
- SGC Apparel
- CYBN Pharmaceuticals and Biotechnology
- Sector
- SGC Consumer Discretionary
- CYBN Health Care
- Exchange
- SGC Nasdaq
- CYBN Nasdaq
- Market Cap
- SGC 163.3M
- CYBN 174.9M
- IPO Year
- SGC N/A
- CYBN N/A
- Fundamental
- Price
- SGC $10.24
- CYBN $7.87
- Analyst Decision
- SGC Strong Buy
- CYBN Strong Buy
- Analyst Count
- SGC 3
- CYBN 4
- Target Price
- SGC $17.00
- CYBN $86.00
- AVG Volume (30 Days)
- SGC 46.2K
- CYBN 320.5K
- Earning Date
- SGC 08-05-2025
- CYBN 08-07-2025
- Dividend Yield
- SGC 5.43%
- CYBN N/A
- EPS Growth
- SGC N/A
- CYBN N/A
- EPS
- SGC 0.45
- CYBN N/A
- Revenue
- SGC $563,931,000.00
- CYBN N/A
- Revenue This Year
- SGC N/A
- CYBN N/A
- Revenue Next Year
- SGC $4.31
- CYBN N/A
- P/E Ratio
- SGC $22.96
- CYBN N/A
- Revenue Growth
- SGC 2.28
- CYBN N/A
- 52 Week Low
- SGC $9.11
- CYBN $4.81
- 52 Week High
- SGC $20.75
- CYBN $13.88
- Technical
- Relative Strength Index (RSI)
- SGC 51.97
- CYBN 49.96
- Support Level
- SGC $9.64
- CYBN $7.11
- Resistance Level
- SGC $10.22
- CYBN $8.19
- Average True Range (ATR)
- SGC 0.34
- CYBN 0.57
- MACD
- SGC 0.00
- CYBN -0.15
- Stochastic Oscillator
- SGC 53.57
- CYBN 36.36
About SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.